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Figure 1. Schematic illustration of signaling pathways involved in Pilo−, Oxo
−M−, and CCh−induced activation of MAPK/ERK pathway.
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Muscarinic receptors belong to G protein−coupled recep-
tor (GPCR) class and consist of five subtypes (M1 −M5 )
(Pronin et al., 2017). Activations of M1 and M3 receptors
have been known to induces Gq protein (Gq)−mediated acti-
vation of phospholipase Cβ (PLCβ), leading to hydrolysis
phosphatidylinositol 4,5−bisphosphate (PIP2) to inositol 1,4,5
−triphosphate (IP3) and diacylglycerol (DAG). IP3 then acti-
vates IP3 receptors in the endoplasmic reticulum to evokes
Ca2+ mobilization (Lin et al., 2008). Agonists of muscarinic
receptor pilocarpine (Pilo) and carbachol (CCh) have been
known to activate salivary secretions through the activation
of Gq−mediated Ca2+ mobilization.
It has also been reported that muscarinic receptor agonists
induced phosphorylation of ERK (pERK) (Lin et al., 2008 ;
Pronin et al., 2017). In 2008, Lin et al demonstrates that
CCh−induced pERK was attenuated by the prolonged PMA−
treatment. On the other hand, Pilo−induced pERK was PMA
−insensitive and was inhibited by Src inhibitor (PP2) and
EGFR inhibitor (AG−1478). These results indicate that the
CCh− and Pilo−induced pERK was mediated by PKC and
Src−mediated transactivation of EGFR (Src−EGFR path-
way), respectively. An involvement of Gβγ in the Pilo−medi-
ated Src activation has been speculated in this paper (Lin et
al., 2008). Recently, Pronin et al. also reported similar Src−
dependent pERK by Pilo (Pronin et al., 2017). Unlike the
previous paper by Lin et al, this paper suggests an involve-
ment of β−arrestin (βA) on the Src−EGFR pathway.
βA has been known to attenuate G protein signaling by
the receptor desensitization. Recent findings for the involve-
ment of βA in the activation of G protein−independent
pathways, such as the MAP kinase pathway (MAPK), have
attracted attention. One of βA signaling functions is scaf-
folding of MAPK cascades. βA also known to induce G
protein−independent pERK through the activation of Src
(Azzi et al., 2003). These current knowledges support the in-
volvement of βA on the Pilo−induced transactivation of
EGFR.
As indicated above, GPCR signaling is bimodal, the G
protein−mediated and the βA−mediated pathways. Pronin et
al. demonstrated that Pilo−induced pERK was almost com-
pletely eliminated by PP2. In contrast, more than 55% oxot-
remorine−M−induced pERK was still occurred even in the
presence of the saturating concentration PP2, and the re-
maining pERK was completely blocked by PKC inhibitors
(Pronin et al., 2017). These results suggest that Pilo act as
bias agonist, an agonist selectively stimulates either G pro-
tein or βA pathway.
It has been known that MAPK/ERK regulate many critical
signaling pathways such as cell proliferation, differentiation,
apoptosis. However, functions of muscarinic receptor−medi-
ated MAPK/ERK pathways in salivary cell are yet to clearly
defined. Recently, Minagi et al. reported long−term admini-
stration of Pilo showed upregulation of M3 receptor expres-
sion (Minagi et al., 2018). It is possible that Pilo−activated
MAPK/ERK play a role in the upregulation of M3 receptor,
and this idea needs to explored.
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